VRNA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.80%

Insider Buying (Last 12 Months): $378,874.24

Insider Selling (Last 12 Months): $13,411,301.36

Verona Pharma Insider Trading History Chart

Verona Pharma Share Price & Price History

^$15.31

▲ +0.07 (0.46%)

As of 04/25/2024 06:13 PM ET

Days: 30 | 90 | 365

World’s biggest multibillionaire investor is buying THIS by the ton [picture]

From Stansberry Research | Ad

Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.

Click here to find out what to do.

Verona Pharma Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/20/2023	Martin Edwards	Director	Buy	33,736	$1.84	$62,074.24	144,800
11/6/2023	David R. Ebsworth	Director	Buy	160,000	$1.98	$316,800.00	844,643
11/3/2023	Kathleen A. Rickard	Insider	Sell	58,752	$1.92	$112,803.84	2,840,640
8/7/2023	Claire Poll	General Counsel	Sell	1,512	$2.47	$3,734.64	1,907,367
8/7/2023	David Zaccardelli	CEO	Sell	8,616	$2.47	$21,281.52	16,431,800
8/7/2023	Kathleen A. Rickard	Insider	Sell	1,600	$2.47	$3,952.00	2,872,528
8/4/2023	David Zaccardelli	CEO	Sell	150,000	$2.50	$375,000.00	16,440,416
8/3/2023	Claire Poll	General Counsel	Sell	20,608	$2.54	$52,344.32	1,935,231
8/3/2023	Kathleen A. Rickard	Insider	Sell	50,600	$2.55	$129,030.00	2,902,072
8/3/2023	Mark W. Hahn	CFO	Sell	117,272	$2.54	$297,870.88	15,679,864
8/2/2023	David Zaccardelli	CEO	Sell	73,704	$2.59	$190,893.36	16,707,688
8/1/2023	Claire Poll	General Counsel	Sell	18,608	$2.68	$49,869.44	1,968,783
8/1/2023	Kathleen A. Rickard	Insider	Sell	19,736	$2.68	$52,892.48	2,966,400
8/1/2023	Mark W. Hahn	CFO	Sell	105,944	$2.68	$283,929.92	15,870,840
5/15/2023	Orbimed Advisors Llc	Director	Sell	359,713	$20.08	$7,223,037.04	3,777,778
5/11/2023	Orbimed Advisors Llc	Director	Sell	80,000	$22.26	$1,780,800.00	4,180,691
5/3/2023	Kathleen A. Rickard	Insider	Sell	28,752	$2.65	$76,192.80	2,971,136
5/1/2023	Claire Poll	General Counsel	Sell	80,376	$2.58	$207,370.08	1,979,063
5/1/2023	David Zaccardelli	CEO	Sell	455,536	$2.58	$1,175,282.88	16,887,336
5/1/2023	Kathleen A. Rickard	Insider	Sell	77,424	$2.58	$199,753.92	2,999,888
5/1/2023	Mark W. Hahn	CFO	Sell	455,528	$2.58	$1,175,262.24	15,976,784
2/1/2023	Claire Poll	General Counsel	Sell	152,000	$2.59	$393,680.00	774,256
2/1/2023	David Zaccardelli	CEO	Sell	432,928	$2.56	$1,108,295.68	17,342,872
2/1/2023	Kathleen A. Rickard	Insider	Sell	89,960	$2.56	$230,297.60	3,106,064
2/1/2023	Mark W. Hahn	CFO	Sell	413,168	$2.56	$1,057,710.08	16,432,312
12/22/2022	Claire Poll	General Counsel	Sell	240,000	$2.69	$645,600.00	774,256
12/22/2022	Orbimed Advisors Llc	Director	Sell	3,969,496	$21.77	$86,415,927.92	36,255,896
12/20/2022	David Zaccardelli	CEO	Sell	600,000	$2.12	$1,272,000.00	17,775,800
8/9/2022	David Zaccardelli	CEO	Sell	600,000	$1.75	$1,050,000.00	15,263,560
8/2/2022	Kathleen A. Rickard	Insider	Sell	28,752	$0.70	$20,126.40	2,376,040
8/1/2022	David Zaccardelli	CEO	Sell	32,904	$0.70	$23,032.80	15,863,560
8/1/2022	Mark W. Hahn	CFO	Sell	13,168	$0.70	$9,217.60	14,913,496
5/3/2022	David Zaccardelli	CEO	Sell	32,904	$0.50	$16,452.00	16,351,328
5/3/2022	Kathleen A. Rickard	Insider	Sell	28,752	$0.49	$14,088.48	2,461,224
5/3/2022	Mark W. Hahn	CFO	Sell	12,512	$0.50	$6,256.00	15,381,520
4/11/2022	Kathleen A. Rickard	Insider	Sell	59,720	$0.54	$32,248.80	2,546,408
4/8/2022	Kathleen A. Rickard	Insider	Sell	112,800	$0.59	$66,552.00	2,606,128
2/3/2022	David Zaccardelli	CEO	Sell	52,056	$0.73	$38,000.88
2/2/2022	Mark W. Hahn	CFO	Sell	10,416	$0.76	$7,916.16
2/1/2022	Lisa Deschamps	Director	Sell	11,664	$0.78	$9,097.92
11/2/2021	David Zaccardelli	CEO	Sell	52,056	$0.64	$33,315.84
11/2/2021	Lisa Deschamps	Director	Sell	11,672	$0.66	$7,703.52
11/2/2021	Mark W. Hahn	CFO	Sell	10,416	$0.65	$6,770.40
8/3/2021	David Zaccardelli	CEO	Sell	16,000	$0.76	$12,160.00
8/2/2021	Mark W. Hahn	CFO	Sell	10,416	$0.77	$8,020.32	16,466,800
5/4/2021	Anders Ullman	Director	Sell	12,056	$0.84	$10,127.04

Mysterious Gold Leverage Just Announced

From Stansberry Research | Ad

World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.

Find out what it is and see how you can get in with just a few dollars.

SEC Filings (Institutional Ownership Changes) for Verona Pharma (NASDAQ:VRNA)

85.88% of Verona Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Verona Pharma Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/23/2024	Rice Hall James & Associates LLC	675,757	$10.87M	0.6%	+44.1%	0.836%
4/22/2024	PFG Investments LLC	26,600	$0.43M	0.0%	+49.4%	0.033%
4/22/2024	Vivo Capital LLC	3,610,177	$58.09M	4.6%	-15.1%	4.467%
4/17/2024	Hennion & Walsh Asset Management Inc.	67,365	$1.08M	0.1%	+71.4%	0.083%
3/5/2024	Wellington Management Group LLP	3,783,994	$75.23M	0.0%	-15.3%	4.734%
2/26/2024	Perceptive Advisors LLC	3,866,214	$76.86M	1.7%	-3.5%	4.836%
2/20/2024	Eventide Asset Management LLC	1,377,781	$27.39M	0.4%	+62.1%	1.724%
2/15/2024	Parkman Healthcare Partners LLC	504,742	$10.03M	1.4%	+20.8%	0.631%
2/14/2024	Avidity Partners Management LP	780,900	$15.52M	0.6%	-5.9%	0.977%
2/14/2024	Superstring Capital Management LP	124,040	$2.47M	1.8%	N/A	0.155%
2/14/2024	Artia Global Partners LP	130,790	$2.60M	0.8%	N/A	0.164%
2/14/2024	Bellevue Group AG	839,996	$16.70M	0.3%	-1.9%	1.051%
2/13/2024	Tower Research Capital LLC TRC	4,495	$89K	0.0%	+950.2%	0.006%
2/13/2024	Affinity Asset Advisors LLC	563,824	$11.21M	2.1%	+53.1%	0.705%
2/13/2024	Campbell & CO Investment Adviser LLC	50,836	$1.01M	0.1%	+1.7%	0.064%
2/12/2024	1492 Capital Management LLC	166,038	$3.30M	1.9%	+1.0%	0.220%
2/12/2024	Cape Investment Advisory Inc.	2,001	$40K	0.0%	N/A	0.003%
2/9/2024	US Bancorp DE	42,102	$0.84M	0.0%	-23.4%	0.053%
2/9/2024	D.A. Davidson & CO.	33,400	$0.66M	0.0%	+2.8%	0.042%
2/9/2024	Clearbridge Investments LLC	248,964	$4.95M	0.0%	N/A	0.311%
2/8/2024	Nicholas Investment Partners LP	169,126	$3.36M	0.4%	-85.5%	0.212%
2/8/2024	First Turn Management LLC	1,206,291	$23.98M	3.4%	N/A	1.509%
2/7/2024	Jump Financial LLC	11,350	$0.23M	0.0%	N/A	0.015%
2/1/2024	New York State Common Retirement Fund	29,669	$0.59M	0.0%	+14.3%	0.037%
2/1/2024	Jennison Associates LLC	1,585,385	$31.52M	0.0%	+9.9%	1.983%
1/26/2024	Moody Aldrich Partners LLC	321,161	$6.39M	1.1%	-9.5%	0.402%
1/24/2024	China Universal Asset Management Co. Ltd.	14,878	$0.30M	0.1%	-73.3%	0.019%
1/17/2024	PFG Investments LLC	17,800	$0.35M	0.1%	N/A	0.022%
1/16/2024	Legato Capital Management LLC	24,329	$0.48M	0.1%	+26.1%	0.030%
12/1/2023	Wellington Management Group LLP	4,467,571	$72.82M	0.0%	+3.8%	5.589%
11/30/2023	American Century Companies Inc.	280,126	$4.57M	0.0%	N/A	0.350%
11/15/2023	Kennedy Capital Management LLC	139,601	$2.28M	0.1%	+19.2%	0.022%
11/15/2023	Adage Capital Partners GP L.L.C.	426,931	$6.96M	0.0%	+95.1%	0.067%
11/15/2023	Affinity Asset Advisors LLC	368,329	$6M	1.7%	-17.7%	0.058%
11/15/2023	Glenmede Trust Co. NA	39,005	$0.64M	0.0%	-12.3%	0.006%
11/14/2023	Eventide Asset Management LLC	850,000	$13.86M	0.2%	N/A	0.134%
11/14/2023	Schonfeld Strategic Advisors LLC	190,406	$3.10M	0.0%	-1.3%	0.030%
11/14/2023	Avidity Partners Management LP	830,300	$13.53M	0.5%	-13.0%	0.131%
11/13/2023	Federated Hermes Inc.	2,493,530	$40.65M	0.1%	+49.3%	0.392%
11/13/2023	Rathbones Group PLC	15,976	$0.26M	0.0%	+66.7%	0.003%
11/13/2023	FMR LLC	6,957,958	$113.42M	0.0%	-2.1%	1.095%
11/8/2023	Campbell & CO Investment Adviser LLC	49,974	$0.82M	0.1%	N/A	0.008%
11/8/2023	Moody Aldrich Partners LLC	354,837	$5.78M	1.1%	+3.8%	0.056%
11/2/2023	Rice Hall James & Associates LLC	25,874	$0.42M	0.0%	N/A	0.004%
11/1/2023	Orion Portfolio Solutions LLC	18,316	$0.30M	0.0%	-4.7%	0.003%
10/31/2023	Jennison Associates LLC	1,442,566	$23.51M	0.0%	+3.9%	0.227%
10/31/2023	Cahill Wealth Management LLC	10,445	$0.17M	0.1%	-13.3%	0.002%
10/31/2023	China Universal Asset Management Co. Ltd.	55,684	$0.91M	0.3%	+166.8%	0.009%
10/24/2023	Bank of New York Mellon Corp	26,478	$0.43M	0.0%	-7.1%	0.004%
8/21/2023	Affinity Asset Advisors LLC	447,667	$9.46M	3.3%	-1.1%	0.070%
8/15/2023	HighVista Strategies LLC	34,027	$0.72M	0.3%	-28.7%	0.005%
8/14/2023	Samsara BioCapital LLC	347,500	$7.35M	1.3%	-50.0%	0.055%
8/14/2023	Caption Management LLC	91,562	$1.94M	0.0%	+357.8%	0.014%
8/14/2023	Bellevue Group AG	572,315	$12.10M	0.2%	+117.9%	0.090%
8/11/2023	HAP Trading LLC	43,805	$0.93M	0.2%	N/A	0.007%
8/10/2023	US Bancorp DE	62,825	$1.33M	0.0%	-10.1%	0.010%
8/10/2023	Nicholas Investment Partners LP	1,163,355	$24.59M	1.7%	+23.6%	0.183%
8/4/2023	Rathbones Group PLC	9,584	$0.20M	0.0%	N/A	0.002%
8/3/2023	Jennison Associates LLC	1,388,663	$29.36M	0.0%	+35.0%	0.218%
8/2/2023	Bank of Montreal Can	10,000	$0.22M	0.0%	N/A	0.002%
7/28/2023	Moody Aldrich Partners LLC	341,701	$7.22M	1.4%	-2.8%	0.054%
7/28/2023	China Universal Asset Management Co. Ltd.	20,873	$0.44M	0.1%	+2,321.5%	0.003%
7/27/2023	Virtu Financial LLC	10,910	$0.23M	0.0%	N/A	0.002%
5/16/2023	Fairmount Funds Management LLC	3,127,429	$62.80M	10.8%	+8.8%	3.959%
5/16/2023	Ally Bridge Group NY LLC	487,631	$9.79M	12.8%	N/A	0.617%
5/16/2023	Altium Capital Management LP	25,000	$0.50M	0.3%	-88.4%	0.032%
5/15/2023	Affinity Asset Advisors LLC	452,821	$9.09M	3.0%	+8.5%	0.573%
5/12/2023	Mirabella Financial Services LLP	29,383	$10.35M	1.6%	-36.0%	0.037%
5/12/2023	Wellington Management Group LLP	3,291,473	$66.09M	0.0%	-1.6%	4.167%
5/12/2023	Nicholas Investment Partners LP	941,300	$18.90M	1.4%	N/A	1.192%
5/11/2023	Tucker Asset Management LLC	2,446	$49K	0.0%	N/A	0.003%
5/11/2023	FMR LLC	4,567,179	$91.71M	0.0%	+110.1%	5.782%
5/9/2023	Tower Research Capital LLC TRC	4,534	$91K	0.0%	+520.2%	0.006%
5/9/2023	Aisling Capital Management LP	1,115,352	$22.40M	10.8%	-16.3%	1.412%
5/9/2023	US Bancorp DE	69,901	$1.40M	0.0%	+40.5%	0.088%
5/8/2023	Cahill Wealth Management LLC	12,045	$0.24M	0.2%	+23.5%	0.015%
5/8/2023	Federated Hermes Inc.	402,050	$8.07M	0.0%	N/A	0.509%
5/5/2023	Carlyle Group Inc.	2,457,500	$49.35M	1.5%	N/A	3.111%
4/28/2023	SG Americas Securities LLC	5,235	$0.11M	0.0%	N/A	0.007%
4/27/2023	Moody Aldrich Partners LLC	351,670	$7.06M	1.4%	+59.0%	0.445%
4/27/2023	Stratos Wealth Partners LTD.	11,540	$0.23M	0.0%	-37.1%	0.015%
4/26/2023	Jennison Associates LLC	1,028,998	$20.66M	0.0%	-0.2%	1.303%
4/25/2023	D.A. Davidson & CO.	32,500	$0.65M	0.0%	-4.4%	0.041%
2/16/2023	Caligan Partners LP	183,064	$4.78M	3.8%	N/A	0.242%
2/15/2023	Fairmount Funds Management LLC	2,875,526	$75.14M	11.9%	+7.3%	3.803%
2/15/2023	Artia Global Partners LP	39,951	$1.04M	0.4%	N/A	0.053%
2/14/2023	RA Capital Management L.P.	6,317,990	$165.09M	3.3%	+4.4%	8.355%
2/13/2023	Northeast Financial Consultants Inc	8,700	$0.23M	0.0%	N/A	0.012%
2/9/2023	Jennison Associates LLC	1,030,627	$26.93M	0.0%	N/A	1.363%
2/7/2023	AlphaCentric Advisors LLC	55,000	$1.44M	1.4%	+37.5%	0.073%
2/7/2023	Commonwealth Equity Services LLC	12,509	$0.33M	0.0%	N/A	0.017%
2/7/2023	Envestnet Asset Management Inc.	25,754	$0.67M	0.0%	+59.1%	0.034%
2/3/2023	Frazier Life Sciences Management L.P.	2,815,720	$73.58M	4.6%	+34.1%	3.724%
2/3/2023	D.A. Davidson & CO.	34,000	$0.89M	0.0%	-15.0%	0.045%
2/1/2023	DekaBank Deutsche Girozentrale	20,000	$0.50M	0.0%	N/A	0.026%
1/24/2023	Moody Aldrich Partners LLC	221,183	$5.78M	1.2%	-3.0%	0.292%
11/15/2022	Perceptive Advisors LLC	5,047,264	$51.58M	1.5%	+73.1%	6.936%
11/15/2022	Pura Vida Investments LLC	100,000	$1.02M	0.1%	N/A	0.137%
11/15/2022	Parkman Healthcare Partners LLC	323,273	$3.30M	0.9%	N/A	0.444%
11/14/2022	NEA Management Company LLC	5,584,753	$57.08M	2.8%	+9.3%	7.675%

Data available starting January 2016

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Today's Range

Now: $15.31

$14.90

$15.45

50 Day Range

MA: $16.40

$15.24

$18.19

52 Week Range

Now: $15.31

$11.83

$23.81

Volume

499,479 shs

Average Volume

496,485 shs

Market Capitalization

$1.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4

Who are the company insiders with the largest holdings of Verona Pharma?: Verona Pharma's top insider shareholders include:
Orbimed Advisors Llc (Director)
David Zaccardelli (CEO)
Mark W Hahn (CFO)
Kathleen A Rickard (Insider)
Claire Poll (General Counsel)
David R Ebsworth (Director)
Martin Edwards (Director)
Learn More about top insider investors at Verona Pharma.
Who are the major institutional investors of Verona Pharma?: Verona Pharma's top institutional investors include:
Vivo Capital LLC — 4.47%
Rice Hall James & Associates LLC — 0.84%
Hennion & Walsh Asset Management Inc. — 0.08%
PFG Investments LLC — 0.03%
Simplex Trading LLC — 0.00%
Learn More about top institutional investors of Verona Pharma stock.
Which major investors are selling Verona Pharma stock?: Within the previous quarter, VRNA stock was sold by these institutional investors:
Vivo Capital LLC
Simplex Trading LLC
Within the last year, company insiders that have sold Verona Pharma company stock include:
Orbimed Advisors Llc (Director)
David Zaccardelli (CEO)
Mark W Hahn (CFO)
Kathleen A Rickard (Insider)
Claire Poll (General Counsel)
Learn More investors selling Verona Pharma stock.
Which major investors are buying Verona Pharma stock?: In the last quarter, VRNA stock was bought by institutional investors including:
Rice Hall James & Associates LLC
Hennion & Walsh Asset Management Inc.
PFG Investments LLC
Within the last year, these company insiders have bought Verona Pharma stock:
Orbimed Advisors Llc (Director)
David Zaccardelli (CEO)
Learn More investors buying Verona Pharma stock.